Boehringer Ingelheim, 3T Biosciences enter into second partnership for cancer immunotherapies

“At Boehringer Ingelheim, we are committed to transforming patients’ lives. The initial success of our work with 3T gives us confidence that together we can and will expand and accelerate our pipeline of first-in-class T-cell based anti-cancer therapies,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology and Immune Modulation, Boehringer Ingelheim.

“The work we have done with Boehringer Ingelheim over the past year provides a higher degree of validation of our 3T-TRACE discovery platform,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “Based on the success of this initial work, we will now go broader and deeper into other cancers.”

Under the agreement, Boehringer Ingelheim will provide patient-derived T-cell receptor (TCR) data to fuel 3T’s target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones for both agreements totaling $538.5 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.